Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA Pharmaceutical Investing
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 Psychedelics Investing
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer Pharmaceutical Investing
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference Pharmaceutical Investing
Merck's KEYTRUDA® Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma Life Science Investing
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference Pharmaceutical Investing
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend Pharmaceutical Investing
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results Pharmaceutical Investing
Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity Medical Device Investing
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 Pharmaceutical Investing
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
